New Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP

WASHINGTON, Sept. 23, 2026 /PRNewswire/ -- The Rare Access Action Project (RAAP) announced today that Bristol Myers Squibb (BMS) has joined RAAP as its newest member, expanding the coalition of patient and life sciences stakeholders working together to address access and coverage challenges affecting people living with rare diseases.

"We are pleased to welcome Bristol Myers Squibb to the Rare Access Action Project," said Michael Eging, Executive Director of RAAP. "BMS brings a long history of scientific innovation and a strong commitment to patients facing serious and complex diseases. Their participation will add an important perspective to our work as we seek practical policy solutions that protect patient access to innovative treatments and care."

Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. The company's core therapeutic areas include oncology, hematology, immunology, cardiovascular disease and neuroscience. Through scientific research and collaboration, BMS works to advance transformational medicines and improve outcomes for patients around the world.

"Patients living with rare and serious diseases often face significant challenges in accessing the treatments and care they need," said Mary Bordoni, Executive Director, Alliance Development, Bristol Myers Squibb. "As we join the Rare Access Action Project, we're proud to collaborate with patient advocates and other stakeholders on policies helping patients prevail over serious diseases, supporting meaningful, sustainable access to innovative medicines. We look forward to contributing to RAAP's work and its commitment to putting patients first in the access discussion."

Eging added that participation from companies such as BMS strengthens RAAP's ability to bring together different perspectives from across the rare disease community.

"Solving access challenges requires collaboration," Eging said. "Patients, advocates, policymakers and innovators all have a role to play. Bringing these voices together allows us to better understand where barriers exist and develop solutions that can make a meaningful difference for rare disease patients and their families."

RAAP, the Rare Access Action Project, is a coalition of patient and life sciences stakeholders that explore creative policy solutions to address structural issues in access and coverage. Our priority is to help ensure rare disease patients have access to the care and treatments they need.

SOURCE Rare Access Action Project (RAAP)